Radium Ra 223
Brand names: Xofigo · Active ingredient: Radium Ra-223 Dichloride
In short: Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
What is Radium Ra 223 used for?
Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
Radium Ra 223 dosage
The dose regimen of Xofigo is 55 kBq (1.49 microcurie) per kg body weight, given at 4 week intervals for 6 injections. Safety and efficacy beyond 6 injections with Xofigo have not been studied.
The volume to be administered to a given patient should be calculated using the:
•Patient’s body weight (kg)
•Dosage level 55 kBq/kg body weight or 1.49 microcurie/kg body weight
•Radioactivity concentration of the product (1,100 kBq/mL; 30 microcurie/mL) at the reference date
•Decay correction factor to correct for physical decay of radium-223.
The total volume to be administered to a patient is calculated as follows:
Volume to be administered (mL) | = | Body weight in kg × 55 kBq/kg body weight
Decay factor × 1,100 kBq/mL
or
Volume to be administered (mL) | = | Body weight in kg × 1.49 microcurie/kg body weight
Decay factor × 30 microcurie/mL
Days from Reference Date | Decay Factor | Days from Reference Date | Decay Factor
-14 | 2.296 | 0 | 0.982
-13 | 2.161 | 1 | 0.925
-12 | 2.034 | 2 | 0.870
-11 | 1.914 | 3 | 0.819
-10 | 1.802 | 4 | 0.771
-9 | 1.696 | 5 | 0.725
-8 | 1.596 | 6 | 0.683
-7 | 1.502 | 7 | 0.643
-6 | 1.414 | 8 | 0.605
-5 | 1.330 | 9 | 0.569
-4 | 1.252 | 10 | 0.536
-3 | 1.178 | 11 | 0.504
-2 | 1.109 | 12 | 0.475
-1 | 1.044 | 13 | 0.447
14 | 0.420
The Decay Correction Factor Table is corrected to 12 noon Central Standard Time (CST). To determine the decay correction factor, count the number of days before or after the reference date. The Decay Correction Factor Table includes a correction to account for the 7 hour time difference between 12 noon Central European Time (CET) at the site of manufacture and 12 noon US CST, which is 7 hours earlier than CET.
Immediately before and after administration, the net patient dose of administered Xofigo should be determined by measurement in an appropriate radioisotope dose calibrator that has been calibrated with a National Institute of Standards and Technology (NIST) traceable radium-223 standard (available upon request from Bayer) and corrected for decay using the date and time of calibration. The dose calibrator must be calibrated with nationally recognized standards, carried out at the time of commissioning, after any maintenance procedure that could affect the dosimetry and at intervals not to exceed one year.
Administer Xofigo by slow intravenous injection over 1 minute.
Flush the intravenous access line or cannula with isotonic saline before and after injection of Xofigo.
Discard any unused portion, if applicable .
Xofigo (an alpha particle-emitting pharmaceutical) should be received, used and administered only by authorized persons in designated clinical settings. …
How to take Radium Ra 223 — instructions & advice from the label
Bone Marrow Suppression
Increased Fractures and Mortality in Combination with Abiraterone plus Prednisone/Prednisolone
Fluid Status
Instructions for Use/Handling
Embryo-Fetal Toxicity
Infertility
•Advise patients to be compliant with blood cell count monitoring appointments while receiving Xofigo. Explain the importance of routine blood cell counts. Instruct patients to report signs of bleeding or infections .
Increased Fractures and Mortality in Combination with Abiraterone plus Prednisone/Prednisolone
•Advise patients that Xofigo had increased bone fractures and mortality when used in combination with abiraterone acetate and prednisone/prednisolone. Inform patients to speak with their healthcare provider about any other medications they are currently taking for prostate cancer .
Fluid Status
•Advise patients to stay well hydrated and to monitor oral intake, fluid status, and urine output while being treated with Xofigo. Instruct patients to report signs of dehydration, hypovolemia, urinary retention, or renal failure / insufficiency . …
Warnings & precautions
Do not take this medicine if: None.
In the randomized trial, 2% of patients on the Xofigo arm experienced bone marrow failure or ongoing pancytopenia compared to no patients treated with placebo. There were two deaths due to bone marrow failure and for 7 of 13 patients treated with Xofigo, bone marrow failure was ongoing at the time of death. Among the 13 patients who experienced bone marrow failure, 54% required blood transfusions. Four percent (4%) of patients on the Xofigo arm and 2% on the placebo arm permanently discontinued therapy due to bone marrow suppression.
In the randomized trial, deaths related to vascular hemorrhage in association with myelosuppression were observed in 1% of Xofigo-treated patients compared to 0.3% of patients treated with placebo. The incidence of infection-related deaths (2%), serious infections (10%), and febrile neutropenia (<1%) were similar for patients treated with Xofigo and placebo. Myelosuppression; notably thrombocytopenia, neutropenia, pancytopenia, and leukopenia; has been reported in patients treated with Xofigo. In the randomized trial, complete blood counts (CBCs) were obtained every 4 weeks prior to each dose and the nadir CBCs and times of recovery were not well characterized. In a separate single-dose phase 1 study of Xofigo, neutrophil and platelet count nadirs occurred 2 to 3 weeks after Xofigo administration at doses that were up to 1 to 5 times the recommended dose, and most patients recovered approximately 6 to 8 weeks after administration .
Hematologic evaluation of patients must be performed at baseline and prior to every dose of Xofigo. Before the first administration of Xofigo, the absolute neutrophil count (ANC) should be ≥ 1.5 x 109/L, the platelet count ≥ 100 x 109/L and hemoglobin ≥ 10 g/dL. Before subsequent administrations of Xofigo, the ANC should be ≥ 1 x 109/L and the platelet count ≥ 50 x 109/L. …
Radium Ra 223 side effects
The following serious adverse reactions are discussed in greater detail in another section of the label:
•Bone Marrow Suppression
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In the randomized clinical trial in patients with metastatic castration-resistant prostate cancer with bone metastases, 600 patients received intravenous injections of 55 kBq/kg (1.49 microcurie/kg) of Xofigo and best standard of care and 301 patients received placebo and best standard of care once every 4 weeks for up to 6 injections. Prior to randomization, 58% and 57% of patients had received docetaxel in the Xofigo and placebo arms, respectively. The median duration of treatment was 20 weeks (6 cycles) for Xofigo and 18 weeks (5 cycles) for placebo.
The most common adverse reactions (≥ 10%) in patients receiving Xofigo were nausea, diarrhea, vomiting, and peripheral edema (Table 3). Grade 3 and 4 adverse events were reported among 57% of Xofigo-treated patients and 63% of placebo-treated patients. The most common hematologic laboratory abnormalities in Xofigo-treated patients (≥ 10%) were anemia, lymphocytopenia, leukopenia, thrombocytopenia, and neutropenia (Table 4). …
Drug interactions
No formal clinical drug interaction studies have been performed.
Subgroup analyses indicated that the concurrent use of bisphosphonates or calcium channel blockers did not affect the safety and efficacy of Xofigo in the randomized clinical trial.
About this medicine
Radium Ra 223 dichloride, an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug.
Xofigo is supplied as a clear, colorless, isotonic, and sterile solution to be administered intravenously with pH between 6 and 8.
Each milliliter of solution contains 1,100 kBq radium-223 dichloride (30 microcurie), corresponding to 0.58 ng radium-223, at the reference date. Radium is present in the solution as a free divalent cation.
Each vial contains 6 mL of solution (6,600 kBq (178 microcurie) radium-223 dichloride at the reference date). The inactive ingredients are 6.3 mg/mL sodium chloride USP (tonicity agent), 7.2 mg/mL sodium citrate USP (for pH adjustment), 0.2 mg/mL hydrochloric acid USP (for pH adjustment), and water for injection USP.
The molecular weight of radium-223 dichloride, 223RaCl2, is 293.9 g/mol.
Radium-223 has a half-life of 11.4 days. The specific activity of radium-223 is 1.9 MBq (51.4 microcurie)/ng.
The six-stage-decay of radium-223 to stable lead-207 occurs via short-lived daughters, and is accompanied predominantly by alpha emissions. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID a398400e-bd31-41a9-9696-4f7c06569ede. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate